(NASDAQ:TGTX), NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and […]

(NASDAQ:BVS), DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann(TM) and StimTrial(TM), expanding the Company's innovative portfolio of Peripheral Nerve Stimulation (PNS) solutions for chronic pain

(TSX:ARG),(OTC US:ARREF),(Other OTC:ARREF), Q2-2025 Net Income of $7.5 million Robust EBITDA1 of $17.8 million and Free Cash Flow to Equity1 of $6.5 million 16th Consecutive Quarterly Dividend of Cdn$0.03 Declared $7.6 million Returned through Dividends and Share Buybacks in Q2-2025 VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX:

(NASDAQ:FXNC), STRASBURG, Va., July 30, 2025 (GLOBE NEWSWIRE) — First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank (the “Bank”), reported earnings for the quarter ended June 30, 2025 of $5.05 million and basic and diluted earnings per common share of $0.56. Excluding acquisition-related items, adjusted earnings(1)

(NASDAQ:CREX),(NASDAQ:CREXW), LOUISVILLE, K.Y., July 30, 2025 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended June 30, 2025 before the market open on Wednesday, August 13, 2025.

(Other OTC:PETV),(OTC US:PETV),(OTC US:PETVW),(Other OTC:PETVW), MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQX PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively “PetVivo” or the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals,

(NasdaqGM:SNSE), BOSTON, July 30, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo(R) (cemiplimab),

TORONTO and KAMLOOPS, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) — Foundation Wealth Partners Inc. (“Foundation Wealth Partners” or “Foundation Wealth”) is proud to announce the promotion of Michael Lynn, CIM(R), FCSI(R), PFP(R), to Partner. Based in Kamloops, British Columbia, Michael brings over 17 years of experience in financial planning and portfolio management. He has

(NasdaqGM:NEXN), NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, will release its financial results for the three and six months ended June 30, 2025, before the U.S. market opens on Wednesday, August

IMT-380 induces selective depletion of pathogenic CD161+ T cells, reducing inflammatory cytokine expression across in vitro and in vivo autoimmune disease models Presented data support anti-CD161 therapy as a novel approach for the treatment of autoimmune diseases Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and developing novel, antibody-based therapeutics for